Implementing a standardized day 1 discharge protocol after minimally invasive colon surgery safely reduces hospital length of stay.
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch ...
Agenus (AGEN) reported that 72% of patients with locally advanced colon cancer had no detectable cancer remaining at surgery after receiving a six-week course of its experimental immunotherapy ...
Abbott’s WGS-based Oncodetect MRD test showed a 30% sensitivity improvement for post-surgical colorectal cancer recurrence.
For more than 12 years, Abbott's cancer diagnostics business has helped expand access to colorectal cancer screening through ...
A retrospective quasi-experimental study links multidisciplinary nursing education with better adherence, psychological ...
A single-patient case report documents bilateral ovarian metastases from colon cancer that ruptured 19 months after curative ...
Hello! This is Odaiba.This time, I will talk about my father's surgery after being hospitalized and the long-term care ...
Welltica+ on MSN
Nearly three years on, this pre-surgery drug kept bowel cancer away in all 32 patients
The approach only works for a specific genetic subtype of bowel cancer, and the researchers now say they can predict who it ...
Allegations that Dr Uzkalnis drank alcohol on duty, injured a patient's bowel, abandoned a procedure and left the operating ...
Agenus reported 72% pathologic complete response in dMMR colon cancer patients using botensilimab/balstilimab, but shares ...
For decades, the standard of care for patients with resected stage II and III colon cancer has centred on surgery with consideration of postoperative adjuvant systemic therapy to reduce risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results